Peptide LibraryPlecanatide
Plecanatide is an FDA-approved guanylate cyclase-C agonist. Plecanatide is a 16-amino-acid analog of the endogenous peptide uroguanylin and, unlike linaclotide, retains uroguanylin’s pH-sensitive binding: its activity at guanylate cyclase-C is greatest in the slightly acidic environment of the proximal small intestine.
For research use only.
Key Facts
- CAS
- 467426-54-6
- Molecular Weight (MW)
- 1681.9 g/mol
- Half-life
- —
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Oral
- Frequency
- Once daily, with or without food
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Orally administered uroguanylin analog approved for chronic idiopathic constipation and for irritable bowel syndrome with constipation. Like linaclotide it acts locally on intestinal epithelium with minimal systemic exposure.
Research evidence
- Regulatory review (FDA label)2 reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Plecanatide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Plecanatide dosage evidence
Plecanatide has an FDA-approved human dosage. Trulance for adults with chronic idiopathic constipation or IBS with constipation is 3 mg by mouth once daily, with or without food.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 3 mg once daily |
| Route | Oral |
| Frequency | Once daily, with or without food |
| Duration studied | Continuous |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Trulance, chronic idiopathic constipationFDA-approved label · FDA prescribing information | Adults with chronic idiopathic constipation | 3 mg | Oral, tablet swallowed whole | Once daily | — | Treatment of chronic idiopathic constipation | TRULANCE (plecanatide) tablets — FDA prescribing information, DailyMed |
| FDA label — Trulance, IBS with constipationFDA-approved label · FDA prescribing information | Adults with IBS with constipation | 3 mg | Oral, tablet swallowed whole | Once daily | — | Treatment of IBS with constipation | TRULANCE (plecanatide) tablets — FDA prescribing information, DailyMed |
Where sources disagree
- Trulance is approved only for adults. Its boxed warning makes it contraindicated under 6 years of age, after deaths from dehydration in young juvenile mice, and says to avoid it from 6 to under 18.
- The label notes plecanatide is minimally absorbed: plasma levels after a 3 mg dose were mostly below the limit of quantitation, so no half-life could be calculated.
Sequence & molecular data
| Molecular formula | C65H104N18O26S4 |
|---|---|
| Molecular weight | 1681.9 g/mol |
| CAS number | 467426-54-6 |
| PubChem CID | 70693500 |
| FDA UNII | 7IK8Z952OK |
| ChEMBL | CHEMBL2103867 |
| DrugBank | DB13170 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Plecanatide is a 16-amino-acid analog of the endogenous peptide uroguanylin and, unlike linaclotide, retains uroguanylin’s pH-sensitive binding: its activity at guanylate cyclase-C is greatest in the slightly acidic environment of the proximal small intestine. Receptor activation raises cyclic GMP, driving chloride and bicarbonate secretion into the lumen and increasing intestinal fluid and transit.
Studies
- Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
- Plecanatide for the treatment of constipation-predominant irritable bowel syndrome
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis
- Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome
- Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome
Research statistics
90 PubMed publications · 31.0% human clinical research · 15 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Plecanatide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
—
Plecanatide side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Plecanatide: frequently asked questions
What is Plecanatide?
Orally administered uroguanylin analog approved for chronic idiopathic constipation and for irritable bowel syndrome with constipation. Like linaclotide it acts locally on intestinal epithelium with minimal systemic exposure.
How does Plecanatide work?
Plecanatide is a 16-amino-acid analog of the endogenous peptide uroguanylin and, unlike linaclotide, retains uroguanylin’s pH-sensitive binding: its activity at guanylate cyclase-C is greatest in the slightly acidic environment of the proximal small intestine. Receptor activation raises cyclic GMP, driving chloride and bicarbonate secretion into the lumen and increasing intestinal fluid and transit.
Is Plecanatide FDA approved?
Yes. Plecanatide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Plecanatide?
Compounds most often compared with Plecanatide include Teduglutide, Linaclotide, Larazotide and Secretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial — Drugs, 2025External reference
- Plecanatide for the treatment of constipation-predominant irritable bowel syndrome — Expert Rev Gastroenterol Hepatol, 2020External reference
- Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis — Lancet Gastroenterol Hepatol, 2019External reference
- Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome — Am J Med, 2019External reference
- Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome — Expert Opin Pharmacother, 2018External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Plecanatide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Plecanatide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →